<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>LIBRA phase 3 trial &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/libra-phase-3-trial/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 21 May 2025 23:06:05 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>LIBRA phase 3 trial &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Short vs. Long Levetiracetam in Brain Tumors</title>
		<link>https://bioengineer.org/short-vs-long-levetiracetam-in-brain-tumors/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 21 May 2025 23:06:05 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[antiseizure medication efficacy]]></category>
		<category><![CDATA[levetiracetam duration brain tumors]]></category>
		<category><![CDATA[LIBRA phase 3 trial]]></category>
		<category><![CDATA[postoperative seizure prevention]]></category>
		<category><![CDATA[seizure management neuro-oncology]]></category>
		<guid isPermaLink="false">https://bioengineer.org/short-vs-long-levetiracetam-in-brain-tumors/</guid>

					<description><![CDATA[In the evolving landscape of neuro-oncology, managing seizures in patients with primary brain tumors remains a critical clinical challenge. Seizures significantly affect both the quality of life and healthcare resources for these patients. Among antiseizure medications (ASMs), levetiracetam has emerged as the most frequently prescribed agent due to its favorable side effect profile and efficacy. [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">246238</post-id>	</item>
	</channel>
</rss>
